Background: Implantable defibrillators (ICD) are an important therapy for arrhythmogenic right ventricular cardiomyopathy (ARVC) patients at high risk of sudden death. Given the high appropriate ICD therapy rate, some have argued that the mere act of implanting an ICD inflates the malignant arrhythmia rate in ARVC.
INTRODUCTION
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease characterized by ventricular arrhythmias and sudden death. 1 Implantable cardiac defibrillators (ICD) are the only proven intervention that protects against sudden death. 2 This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. Large series show 40-70% patients have appropriate ICD therapy for sustained ventricular arrhythmias after implantation. [3] [4] [5] Therefore, some have argued that the mere act of implanting an ICD inflates the malignant arrhythmia rate in ARVC. However, there is a paucity of data characterizing arrhythmic outcomes in not affected by
ICDs.
A critical decision after ARVC diagnosis is whether a patient's sudden death risk justifies ICD placement. However, most studies about risk stratification in ARVC either only comprised patients with ICDs 4, [6] [7] [8] [9] [10] [11] [12] or included significant portions of patients with ICDs. [13] [14] [15] [16] [17] This is problematic because appropriate ICD therapy for ventricular arrhythmias occurs more frequently than sudden death in nonischemic cardiomyopathy. 18, 19 Also, predictors for appropriate ICD therapy may not necessarily be extrapolated to predicting sudden death. Therefore, it is informative to study ARVC patients who have not previously undergone ICD implantation.
Brun et al. 20 attempted to address this important question by analyzing 88 ARVC patients without ICDs. However, most of the patients included were diagnosed prior to adoption of the 2010 Task Force Criteria for diagnosis of ARVC. 21, 22 Our study aims to report the arrhythmic course of a contemporary cohort of ARVC patients with complete phenotype and genotype data. For the first time, the reasons of nonimplantation were systemically reported and correlated to the arrhythmic outcomes. This will provide insight concerning the risk of sudden death and ventricular arrhythmias in ARVC and inform interpretation of previous studies which used appropriate ICD therapy as the outcome.
METHODS

Patient selection
The study population was from the Johns Hopkins ARVC Registry, which has prospectively enrolled ARVC patients and their family members since 1999. Among 459 patients who met the 2010 Task Force Criteria 21 for ARVC and in whom at least 6 months of follow-up information was available, we identified 131 who had no ICD implanted for a minimum of 6 months after initially meeting the 2010 diagnostic criteria for ARVC, 47 of whom had no ICD at last follow-up. All patients provided written informed consent. The Johns Hopkins School of Medicine Institutional Review Board approved the study.
Endpoints
The primary endpoint was a composite of cardiac arrest, sudden cardiac death, and sustained ventricular tachycardia. A sustained ventricular tachycardia was defined as a tachycardia originating in the ventricles with a rate of >100 beats per minute and a duration at least 30 seconds or that requires an intervention for termination.
Covariates
Baseline data were collected at the time of meeting the Task Force Criteria and included sex, date of birth, date and type of presentation, 
Statistical analysis
RESULTS
Baseline characteristics
This study included 131 ARVC patients (51 male, 38.9%) who met the Task Force Criteria at the median age of 34 years. Half were probands.
They were followed for a median of 8 years after the fulfillment of the diagnostic criteria. Two-thirds carried a PKP2 mutation. Two patients carried digenic mutations. Prior to fulfilling the diagnostic criteria, most patients were physically active ( Table 1) .
At the time that the 2010 diagnostic criteria were initially fulfilled, less than one-third of these patients had experienced spontaneous sustained ventricular arrhythmias and 5 had survived a cardiac arrest. At the time that the diagnostic criteria were met, beta-blockers were prescribed to 56 patients (43.4%) and antiarrhythmic medications to 28 patients (19.5%). Ablation for ventricular tachycardias was performed in 21 (16.0%) patients. (Table S1 ).
Reason for not implanting an ICD when the diagnostic criteria were fulfilled
An additional 6 patients did not undergo ICD implantation after fulfilling the diagnostic criteria due to pregnancy (4), upcoming hand 
, and digenic mutations (n = 2). b Other antiarrhythmic drugs: mexiletine (n = 2), verapamil (n = 1), disopyramide (n = 3), procainamide (n = 1), quinidine (n = 1).
surgery (1), or insurance approval (1). One patient had the device explanted within 1 month because of infection and declined reimplantation. 
Clinical course
After fulfilling the diagnostic criteria while not being protected by When ARVC was not recognized, the outcomes were particularly poor with 18 patients (45%) having primary endpoints (P value = 0.04 by the log-rank test). When ARVC was recognized, there was no difference in the survival between patients who were deemed at low risk and patients who were deemed at high risk but declined an ICD (P value = 0.47 by the log-rank test). The use of beta-blocker, antiarrhythmic drugs, or ablation for ventricular tachycardias after diagnosis were not associated with ventricular arrhythmias (P value all > 0.05).
Risk factors for malignant ventricular arrhythmias
We next explored the associations between clinical variables and the primary outcome. Univariate analyses confirmed the predictive values of previously reported risk factors, namely spontaneous sustained ventricular arrhythmia, cardiac syncope, male gender, proband, and inducibility on electrophysiology study. Non-sustained ventricular tachycardia, premature ventricular complex more than (Table 2 ). In multivariable analysis, only cardiac syncope and proband remained statistically significant.
DISCUSSION
Main findings
This is the largest study focusing on arrhythmic outcomes in a contemporary cohort of ARVC patients who did not have an ICD. Considerable risk of cardiac arrest and ventricular arrhythmia was observed.
The arrhythmic outcomes did not differ between patients deemed not high enough risk to recommend an ICD and patients who refused ICD despite the recommendation. The arrhythmic risk was particularly high when ARVC was not recognized, highlighting the importance of timely diagnosis. Lastly, spontaneous sustained ventricular arrhythmia, cardiac syncope, male gender, proband, and inducibility on electrophysiology study were confirmed as risk factors associated with malignant arrhythmia. 
Ventricular arrhythmia in ARVC
Most studies reporting arrhythmic outcomes of ARVC focused on patients who have an ICD already. 4, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] In these studies, high event rates have been reported: between 40% and 70% patients had appropriate ICD therapy in 2-9 years after implantation. 3 12 deaths (13.5%) including 6 sudden deaths. However, patients had been recruited into these studies long before 2010. Since then, ARVC patient demographic and risk profiles have evolved due to the revision of diagnostic criteria, introduction of magnetic resonance imaging, genetic testing allowing for earlier diagnosis, and changes in therapies in addition to ICD. 3, [21] [22] [23] In this context, our study revisited the arrhythmic outcomes of ARVC in the absence of ICD implantation in a contemporary cohort.
Although lower than in studies using ICD therapies as an outcome, we still observed a high rate of ventricular arrhythmia: the incidence rate was 6.6 events per 100 person-years and 28% patients experienced arrhythmic events in 5 years after the fulfillment of the diagnostic criteria. Three patients died suddenly. Several factors could contribute to this.
First, by including patients whose ICDs were not implanted within the first 6 months after the fulfillment of the diagnostic criteria, we captured an important group of patients-those who had not had an Abbreviations: CI = confidence interval; EF = ejection fraction; FAC = fractional area change; HR = hazard ratio.
ICD at diagnosis but later suffered arrhythmic events leading to ICD implantation. This group has not been studied previously. We believe that this approach emulates the dynamic process of deciding ICD candidacy in clinical practice and is critical in characterizing the natural history in ARVC patients not having an ICD.
Second, 40 patients who met the Task Force Criteria but were not yet recognized as ARVC had particularly high event rates (45% having primary outcomes). Treating physicians most commonly diagnosed them as normal variant (48%) and were uncertain about the diagnosis in one-third of the cases. The most commonly neglected diagnostic clues were precordial T-wave inversions and abnormalities on MRI.
About one-third of the patients were asymptomatic, but lack of symptoms did not guarantee freedom from arrhythmia because about 60%
of the cardiac arrest victims in ARVC are asymptomatic before their event. 24 This highlights the importance of being aware of the Task Force Criteria, 21 correct interpretation of CMR, 25 and timely efforts to clarify uncertain diagnoses if ARVC is part of the differential. 3, 26 Five patients were misdiagnosed with idiopathic ventricular tachycardia that may mimic ARVC when originating from the right ventricular outflow tract. 27 A scoring system and ectopic QRS morphology have been reported to be effective in making the differential diagnosis. 28,29
Deciding ICD candidacy in ARVC
Whether a patient's sudden death risk justifies ICD implantation is a critical clinical decision in ARVC. Our study sheds light on this from 3 important perspectives.
First, we confirmed the predictive value of previously reported risk factors including spontaneous sustained ventricular arrhythmia, cardiac syncope, male sex, proband status, and inducibility on electrophysiology study. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] By tracking clinically relevant arrhythmic events as the outcome in patients not having ICDs yet, our results should give clinicians more confidence in relying on these risk factors to decide ICD candidacy. Additionally, nonsustained ventricular tachycardia and 24-hour premature ventricular complex count had positive hazard ratios and their lack of significance could be from a power issue. Both were reported as predictive in studies solely comprising patients with
ICDs. 4, 6, 10 Therefore, another possibility is that non-sustained ventricular tachycardia and premature ventricular complex count may be more predictive for ventricular arrhythmia which terminates spontaneously but still triggers therapy in the presence of an ICD.
Second, apart from the risk of sudden cardiac death, patients' preferences are as important in the decision-making process. Our study, for the first time, recorded the reasons the ICD was not implanted at the fulfillment of the diagnostic criteria. In our study, 22 patients refused an ICD despite the recommendation by their physicians. Four had sustained ventricular tachycardia and one died from cardiac arrest with an overall incidence rate of 3.6 events per 100 person-years. This information is helpful in the risk-benefit discussion with patients who are hesitant about having an ICD.
Lastly, our study highlights the need for improvement in risk stratification in ARVC. In the 59 patients whose risk was deemed not high enough to justify an ICD by their physicians (who, as expected,
were more likely to be female, family members, and have less spontaneous sustained ventricular arrhythmia and less PVCs (Table S1 ), their risk remained significant (incidence rate 5.6 events/100 person-years).
This calls for ongoing improvements in risk stratification focusing on larger populations and identification of novel risk factors for sudden death in ARVC.
Limitations
Our study population was from a referral center, which may contribute to the high risk observed and make the results not applicable in nonreferral settings. This is an inherent limitation in studies of rare diseases. Also, the reasons the ICD were not implanted were retrospectively collected. As a result, we may not capture the details that are frequently lost in clinical documentation but may play critical roles in clinical decision making. Because less than 10% of patients in the study carried non-PKP2 mutations, the results may not be applicable to them. Lastly, the high event rate of patients who were not recognized as ARVC despite meeting the Task Force Criteria could reflect some selection bias because they would have likely remained unrecognized if not having the event.
CONCLUSIONS
A considerable risk of cardiac arrest and ventricular arrhythmia exists in ARVC patients without ICDs. The arrhythmic risk was particularly high when ARVC was unrecognized, readdressing the importance of timely diagnosis. Further studies are required to refine risk stratification for sudden death in ARVC.
